Answers are grounded in this paper and cite their sources.
Epidemiological studies have shown that low-density lipoprotein cholesterol (LDL-C) is a strong risk factor for coronary heart disease (CHD), whilst high-density lipoprotein cholesterol (HDL-C) reduces the risk for CHD. Therefore, strategies to manage dyslipidemia in an effort to prevent or treat CHD have primarily attempted to decrease LDL-C and raise HDL-C levels. Cholesteryl ester transfer protein (CETP) inhibitors have proven to be effective in achieving both a reduction in LDL-C and an increase in HDL-C. This review will discuss the current status and future prospects of CETP inhibitors in the treatment of CHD.
No takes yet. Share an insight, caveat, or question.
Mabuchi et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: